IL266568B2 - Conditioned formulations of exendin (39-9) - Google Patents

Conditioned formulations of exendin (39-9)

Info

Publication number
IL266568B2
IL266568B2 IL266568A IL26656819A IL266568B2 IL 266568 B2 IL266568 B2 IL 266568B2 IL 266568 A IL266568 A IL 266568A IL 26656819 A IL26656819 A IL 26656819A IL 266568 B2 IL266568 B2 IL 266568B2
Authority
IL
Israel
Prior art keywords
exendin
pharmaceutical formulation
liquid pharmaceutical
formulation
concentration
Prior art date
Application number
IL266568A
Other languages
English (en)
Hebrew (he)
Other versions
IL266568B1 (en
IL266568A (en
Original Assignee
Eiger Biopharmaceuticals Inc
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc, Univ Leland Stanford Junior filed Critical Eiger Biopharmaceuticals Inc
Publication of IL266568A publication Critical patent/IL266568A/en
Publication of IL266568B1 publication Critical patent/IL266568B1/en
Publication of IL266568B2 publication Critical patent/IL266568B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL266568A 2016-11-21 2017-11-21 Conditioned formulations of exendin (39-9) IL266568B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424979P 2016-11-21 2016-11-21
US201762517065P 2017-06-08 2017-06-08
PCT/US2017/062838 WO2018094404A1 (en) 2016-11-21 2017-11-21 Buffered formulations of exendin (9-39)

Publications (3)

Publication Number Publication Date
IL266568A IL266568A (en) 2019-07-31
IL266568B1 IL266568B1 (en) 2024-05-01
IL266568B2 true IL266568B2 (en) 2024-09-01

Family

ID=62145888

Family Applications (1)

Application Number Title Priority Date Filing Date
IL266568A IL266568B2 (en) 2016-11-21 2017-11-21 Conditioned formulations of exendin (39-9)

Country Status (20)

Country Link
US (4) US11020484B2 (cg-RX-API-DMAC7.html)
EP (2) EP3541366B1 (cg-RX-API-DMAC7.html)
JP (4) JP7584894B2 (cg-RX-API-DMAC7.html)
CN (1) CN110267648A (cg-RX-API-DMAC7.html)
AU (3) AU2017361539B2 (cg-RX-API-DMAC7.html)
CA (1) CA3043899A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001366A1 (cg-RX-API-DMAC7.html)
DK (1) DK3541366T3 (cg-RX-API-DMAC7.html)
ES (1) ES3014024T3 (cg-RX-API-DMAC7.html)
FI (1) FI3541366T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250278T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070730T2 (cg-RX-API-DMAC7.html)
IL (1) IL266568B2 (cg-RX-API-DMAC7.html)
LT (1) LT3541366T (cg-RX-API-DMAC7.html)
PL (1) PL3541366T3 (cg-RX-API-DMAC7.html)
PT (1) PT3541366T (cg-RX-API-DMAC7.html)
RS (1) RS66595B1 (cg-RX-API-DMAC7.html)
SI (1) SI3541366T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500120T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018094404A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456340B1 (en) 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
SMT202500120T1 (it) 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)
IL271245B2 (en) 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CN112867730A (zh) 2018-10-15 2021-05-28 艾格尔峰生物制药有限公司 用于治疗高胰岛素低血糖症的阿维西特
MX2022014090A (es) 2020-05-12 2023-02-27 Regeneron Pharma Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos.
US20240307501A1 (en) 2021-06-21 2024-09-19 Eiger Biopharmaceuticals, Inc. Treatment of congenital hyperinsulinism with avexitide
US11878036B2 (en) * 2022-05-25 2024-01-23 Neuvian LLC Vaginal care compositions and methods of improving vaginal health
CN116606367A (zh) * 2022-05-31 2023-08-18 南京盛德瑞尔医药科技有限公司 长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物
WO2024220962A1 (en) * 2023-04-21 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Glp-1r antagonism to improve nutrition following gastrointestinal surgery
US20260151460A1 (en) * 2024-12-02 2026-06-04 Amylyx Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia
WO2026122473A1 (en) * 2024-12-02 2026-06-11 Amylyx Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1609478A1 (en) * 1999-01-14 2005-12-28 Amylin Pharmaceuticals, Inc. Exendin agonist peptide formulations
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9306551A (pt) 1992-06-15 1998-09-15 Pfizer Derivados de peptídeo do tipo glucagona e de insulinotropina
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
DE69740096D1 (de) 1996-08-08 2011-02-17 Amylin Pharmaceuticals Inc Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ,インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
JP3270761B2 (ja) 1998-01-30 2002-04-02 ノボ ノルディスク アクティーゼルスカブ 注射器
PT1137413E (pt) 1998-12-10 2005-05-31 Agouron Pharma Antagonistas nao-peptidicos do receptor de glp-1 e metodos de utilizacao
JP2002538084A (ja) 1999-01-14 2002-11-12 アミリン・ファーマシューティカルズ,インコーポレイテッド グルカゴンを抑制する方法
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
JP4398644B2 (ja) 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ErbB界面ペプチド擬態およびその使用方法
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN1968700A (zh) 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
PL2347762T3 (pl) 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
SMP200800064B (it) * 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
MX2008015107A (es) * 2006-05-26 2008-12-09 Amylin Pharmaceuticals Inc Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.
EP3456340B1 (en) 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
EP2144649B1 (de) 2007-04-05 2011-07-20 Tecpharma Licensing AG Verabreichungsvorrichtung mit funktionalem antriebsglied
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CA2723434C (en) 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
ES2552646T3 (es) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendinas para disminuir el colesterol y los triglicéridos
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
US9314508B2 (en) 2008-07-08 2016-04-19 Novartis Ag Use of somatostatin analogs in control of hypoglycemia
EP3685837A1 (en) 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
CN102378632A (zh) 2009-04-03 2012-03-14 雀巢产品技术援助有限公司 对促进健康的追赶生长的改进
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2768856A4 (en) 2011-10-18 2015-05-27 Prolynx Llc PEG CONJUGATES OF EXENATIDE
EP2817025A2 (en) 2012-02-08 2014-12-31 Seneb Biosciences, Inc. Treatment of hypoglycemia
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なIgG4に基づく結合剤の製剤
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
SMT202500120T1 (it) 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1609478A1 (en) * 1999-01-14 2005-12-28 Amylin Pharmaceuticals, Inc. Exendin agonist peptide formulations
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARZIEH SALEHI ET AL,, BLOCKADE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR CORRECTS POSTPRANDIAL HYPOGLYCEMIA AFTER GASTRIC BYPASS, 1 March 2014 (2014-03-01) *

Also Published As

Publication number Publication date
BR112019010236A2 (pt) 2019-08-20
EP3541366A4 (en) 2020-08-05
CN110267648A (zh) 2019-09-20
JP2024150450A (ja) 2024-10-23
DK3541366T3 (da) 2025-03-03
PT3541366T (pt) 2025-03-14
IL266568B1 (en) 2024-05-01
US11738086B2 (en) 2023-08-29
HUE070730T2 (hu) 2025-06-28
AU2023237119B2 (en) 2025-04-10
HRP20250278T1 (hr) 2025-04-25
AU2017361539A1 (en) 2019-07-04
SI3541366T1 (sl) 2025-05-30
EP3541366B1 (en) 2024-12-25
AU2025205195A1 (en) 2025-07-24
US20260034221A1 (en) 2026-02-05
CL2019001366A1 (es) 2019-11-08
WO2018094404A1 (en) 2018-05-24
LT3541366T (lt) 2025-03-10
US20210315995A1 (en) 2021-10-14
FI3541366T3 (fi) 2025-03-06
RS66595B1 (sr) 2025-04-30
US20200069802A1 (en) 2020-03-05
SMT202500120T1 (it) 2025-05-12
EP3541366A1 (en) 2019-09-25
US20240042035A1 (en) 2024-02-08
US11020484B2 (en) 2021-06-01
PL3541366T3 (pl) 2025-04-28
CA3043899A1 (en) 2018-05-24
AU2023237119A1 (en) 2023-10-19
JP2019535734A (ja) 2019-12-12
JP2026048629A (ja) 2026-03-17
JP7584894B2 (ja) 2024-11-18
JP2022153624A (ja) 2022-10-12
AU2017361539B2 (en) 2023-06-29
EP4591853A1 (en) 2025-07-30
ES3014024T3 (en) 2025-04-16
IL266568A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
US20260034221A1 (en) Buffered formulations of exendin (9-39)
US11622995B2 (en) Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
JP2019535734A5 (cg-RX-API-DMAC7.html)
US20240350590A1 (en) Composition for orally administered formulation containing glp-1 analogue
HK40014636B (en) Buffered formulations of exendin (9-39)
HK40014636A (en) Buffered formulations of exendin (9-39)
BR112019010236B1 (pt) Formulações tamponadas de exendina (9-39) e uso das mesmas
BR122025006444A2 (pt) Formulações tamponadas de exendina (9-39)
HK40128497A (zh) 使用gip/glp1共激动剂用於治疗的方法